Advanced Brain Cancer: Tissue Freezing

Phil Brickell Excerpts

Wednesday 7th January 2026 Westminster Hall

[Dame Siobhain McDonagh (Mitcham and Morden) (Lab)]

Debates on brain tumours are a bit like buses—there are none for ages, then they all come one after the other. I thank my hon. Friend the Member for Caerphilly (Chris Evans) for organising this debate—the second of two debates on this topic on consecutive days. I send my condolences to Ellie and her entire family on the death of Owain. I think, like a number of people in this room, I understand some of what she has experienced. I have to inform you, Mr Western, that a former Labour MP is close to dying of a glioblastoma—another politician after Tessa Jowell and my sister Margaret. I want to ask: when do we intervene to do something about this, rather than talk about it?

I am supportive of any measure that genuinely improves patient outcomes for glioblastoma patients. Anything that increases survival of this devastating disease is worth supporting, but in my own experience, working closely with clinicians and supporting my late sister through her glioblastoma treatment, the most effective way to improve outcomes for patients with brain tumours is by accessing clinical drug trials. Without trials there is no route to better treatment or lifelines, and for too many patients, no pathway at all.

I think we can all agree that the number of clinical trials under way for brain tumours is entirely inadequate. It is impossible to justify that, since 2008, the National Institute for Health and Care Research has invested just £13.7 million towards brain tumour research and none of the funding to date has supported using repurposed drugs—that is, using some of the immunotherapy drugs that are changing the face of the larger cancers and their outcomes.

[Phil Brickell (Bolton West) (Lab)]

I want to pay tribute to my constituent, Alex Davies, who sadly passed away last November, the day after his 50th birthday, two years after his glioblastoma diagnosis. He is survived by his wife Emma and their two daughters. Alex volunteered to have his brain tissue frozen after two surgeries, for ongoing research at the Christie hospital in Manchester.

Does my hon. Friend agree that the Government’s national cancer plan should include more and better-used funding for research and more clinical trials, particularly for poorly understood cancers such as glioblastoma on which she has campaigned tenaciously over many years?

[Dame Siobhain McDonagh]

My hon Friend is absolutely right. Let us be absolutely clear: there is no route for an improvement in any of the rare cancers unless there are more trials—and the system mitigates against that. There is a lot of talk at the moment about the Government of stakeholders. The stakeholders involved in drug trials—the major pharma companies and cancer charities—do not get involved in these trials because for pharma there is no money in it, and for the big charities, there seems to be more interest in primary science and mice work than there is in using some of these amazing drugs to find out whether they can provide some sort of support to people with rare cancers.

It is the lack of treatment options, and this inaction, that led me, alongside my sister’s extraordinary network of friends and supporters, to launch our own trial in her memory. When the system does not move quickly enough, patients and families are forced to take matters into their own hands. We have an established clinical trial now under way at the University College London Hospitals clinical research facility with encouraging early indicators, a wider trial programme mapped out and further trials ready to follow with protocols written.

We are seeking to clarify how to secure the funding needed to repeat and extend this work using alternative drugs, so that more patients can benefit. We continue to raise funds to support that goal.